Healthcare • NYSE
According to Zyberno, DAVITA INC. (DVA) shows a Value Trap signal — AVERAGE BUSINESS (53/100) with an apparent Margin of Safety of +61.4%, but a Brina Gap of -2.0% reveals the current price still assumes faster growth than the business can deliver.
According to Zyberno's DCF model, DAVITA INC. (DVA) trades at $181.58 against an estimated intrinsic value per share of $470.11 — a +61.4% Margin of Safety based on Owner Earnings of $1.49B TTM, projected at 10.9% growth for 10 years with a 2.5% terminal growth rate. The Brina Gap of -2.0% weakens the case: based on the company's ROIC (16.7%) and reinvestment rate (-0.9%), the business can fundamentally grow at -0.2% — but the current enterprise value implies the market expects 1.8%. This places DVA in the Value Trap quadrant of the Brina Matrix — a value-trap signal where the apparent discount is undermined by overpriced growth expectations. Zyberno's model translates this into a 5-year expected return of 34.1% annually.
Over the trailing twelve months, DVA generated $1.49B in Owner Earnings. Capital was deployed as follows: $196.37M returned via share buybacks, $534.62M invested in capital expenditures. Reinvestment rate: -0.9%. Owner Earnings have grown at 10.9% annually over the trailing five years using log-linear regression.